Abstract
Glaucoma, the multifactorial disease of the eye, is characterized by many biological risk factors as well as genetic factors which lead to degeneration of optic nerves. The major factor which is associated with glaucoma is increase in intraocular pressure (IOP). Treatment for glaucoma should be such that to reduce the IOP either by decreasing the production of aqueous humor or by enhancing its drainage. Currently, the most commonly used approach is the use of conventional ophthalmic eye drops, which accounts for approximately more than 90% of the available marketed ophthalmic dosage forms. Brinzolamide, the carbonic anhydrase inhibitor, in the present study has been formulated as niosomes to provide a sustained action and compared with niosomal in-situ gel loading Brinzolamide. Brinzolamide loaded niosomes had vesicle size of 236.2 ± 3.1 nm and a high zeta potential of −46.2 ± 3.1 mV. A high Encapsulation efficiency of 79.99 ± 2.2% and a sustained release profile in vitro for 24 h. The Niosomal in-situ gel system showed good gelation capacity and adequate spreadability. In-vivo studies conducted on healthy New Zealand white rabbits showed maximum IOP reduction at 8 h and maintained IOP reduction effect till 24 h. The study showed a sustained release of Brinzolamide from the niosomal in-situ gel and a sustained reduction in IOP in rabbits for 24 h with a single administration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.